Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04699838
Title Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Muhammad Furqan
Indications

lung small cell carcinoma

Therapies

Carboplatin + Ceralasertib + Durvalumab + Etoposide

Ceralasertib + Cisplatin + Durvalumab + Etoposide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.